BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29339775)

  • 1. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
    Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
    Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
    Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
    Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.
    Grabow S; Kelly GL; Delbridge AR; Kelly PN; Bouillet P; Adams JM; Strasser A
    Cell Death Dis; 2016 Mar; 7(3):e2132. PubMed ID: 26962682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of apoptosis, Bcl-x and c-Myc in normal and malignant lymphoid tissues.
    Hermann M; Scholman HJ; Marafioti T; Stein H; Schriever F
    Eur J Haematol; 1997 Jul; 59(1):20-30. PubMed ID: 9260577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice.
    Mardilovich K; Naylor G; Julian L; Phinichkusolchit N; Keeshan K; Blyth K; Olson MF
    Dis Model Mech; 2024 May; 17(5):. PubMed ID: 38616733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
    Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
    Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
    Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
    Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc suppression of Nfkb2 accelerates lymphomagenesis.
    Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
    BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling.
    Vier J; Groth M; Sochalska M; Kirschnek S
    Cell Death Dis; 2016 Feb; 7(2):e2103. PubMed ID: 26890142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.
    Michalak EM; Jansen ES; Happo L; Cragg MS; Tai L; Smyth GK; Strasser A; Adams JM; Scott CL
    Cell Death Differ; 2009 May; 16(5):684-96. PubMed ID: 19148184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis.
    Tuzlak S; Haschka MD; Mokina AM; Rülicke T; Cory S; Labi V; Villunger A
    FEBS J; 2018 Apr; 285(8):1403-1418. PubMed ID: 29498802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
    Eischen CM; Woo D; Roussel MF; Cleveland JL
    Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.
    Happo L; Phipson B; Smyth GK; Strasser A; Scott CL
    Cell Death Dis; 2012 May; 3(5):e306. PubMed ID: 22573037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
    Campbell KJ; Bath ML; Turner ML; Vandenberg CJ; Bouillet P; Metcalf D; Scott CL; Cory S
    Blood; 2010 Oct; 116(17):3197-207. PubMed ID: 20631380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3.
    Petrenko O; Li J; Cimica V; Mena-Taboada P; Shin HY; D'Amico S; Reich NC
    PLoS One; 2021; 16(3):e0247394. PubMed ID: 33651821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.
    Hunter JE; Campbell AE; Kerridge S; Fraser C; Hannaway NL; Luli S; Ivanova I; Brownridge PJ; Coxhead J; Taylor L; Leary P; Hasoon MSR; Eyers CE; Perkins ND
    Biochem J; 2022 Oct; 479(19):2131-2151. PubMed ID: 36240067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.
    Deng Y; Diepstraten ST; Potts MA; Giner G; Trezise S; Ng AP; Healey G; Kane SR; Cooray A; Behrens K; Heidersbach A; Kueh AJ; Pal M; Wilcox S; Tai L; Alexander WS; Visvader JE; Nutt SL; Strasser A; Haley B; Zhao Q; Kelly GL; Herold MJ
    Nat Commun; 2022 Aug; 13(1):4739. PubMed ID: 35961968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.